Budd-Chiari syndrome is a rare liver condition in which blood flow out of the liver becomes blocked, causing pressure to build up inside the organ. It affects roughly 1 in every million people per year, though prevalence varies by region. The blockage can occur anywhere from the tiny veins inside the liver to the large vein that carries blood back to the heart, and the consequences range from mild, barely noticeable symptoms to acute liver failure.
How the Blockage Damages the Liver
Your liver constantly filters blood and sends it back toward the heart through a network of veins. In Budd-Chiari syndrome, one or more of these drainage routes becomes obstructed, usually by a blood clot. When blood can’t exit normally, it backs up into the liver’s tiny filtering units, raising pressure inside them. This creates a chain reaction: the liver swells, fluid leaks into the abdomen, and the tissue at the center of each filtering unit starts to die from the congestion.
The blockage also forces blood to find alternate escape routes. Over time, small collateral veins may develop between blocked and unblocked areas, acting as natural bypass channels. Whether this happens quickly enough to prevent serious damage depends largely on how fast the obstruction develops.
What Causes It
In about 75% of cases, at least one blood-clotting disorder can be identified. More than one contributing factor is present in roughly a quarter of patients.
Bone marrow disorders that cause the body to overproduce blood cells are the single largest category, found in about 20% of diagnosed cases. When doctors screen for subtler, hidden forms of these disorders, the number climbs to between 45% and 53%. A genetic clotting mutation called Factor V Leiden appears in about 25% of Western patients and is especially common in cases linked to pregnancy or oral contraceptive use. Inherited deficiencies in natural blood-thinning proteins, particularly protein C, account for another 25%.
Secondary causes, meaning the vein is compressed or invaded rather than clotted, include liver tumors, abscesses, or cysts that physically press on the veins from outside.
Symptoms and the Classic Triad
The hallmark presentation is a combination of three symptoms: abdominal pain (typically in the upper right side), a swollen abdomen from fluid buildup (ascites), and an enlarged liver. Most patients present with some version of this triad, but the severity depends on how the condition develops.
- Fulminant (about 5% of cases): Rapid onset with severe liver failure, kidney problems, and abnormal clotting. This is a medical emergency.
- Acute (about 20%): Develops within a month. Marked by intense ascites, pain, liver swelling, and rising liver enzymes.
- Subacute or chronic (about 60%): The most common form. Symptoms creep in over weeks to months. The slow pace gives the body time to develop collateral veins, which can partially compensate for the blockage. Chronic cases eventually lead to cirrhosis and portal hypertension.
- Asymptomatic (15 to 20%): When only one hepatic vein is blocked or collateral veins form early, some people have no symptoms at all and the condition is discovered incidentally.
How It Is Diagnosed
Doppler ultrasound is typically the first imaging test and can reveal several characteristic findings: reduced or absent blood flow in the hepatic veins, reversed flow direction, and a distinctive “spiderweb” pattern of tiny collateral vessels near the vein openings. This spiderweb appearance, when seen on angiography, is considered a hallmark sign of the disease.
CT and MRI scans can add further detail. A specific sign called the “IVC reverse flow sign” on these scans points to obstruction in the large vein leading to the heart. If a membrane with a small perforation is causing the blockage, imaging may show a “jet-blood” sign where blood squeezes through the narrow opening.
Treatment: A Step-by-Step Approach
Treatment follows a stepwise strategy, starting with the least invasive option and escalating only when needed.
Blood Thinners
The first step for nearly all patients is long-term anticoagulation therapy to prevent existing clots from growing and new ones from forming. This is especially important because the underlying clotting tendency doesn’t go away on its own. Treating the root cause, such as a bone marrow disorder, happens in parallel.
Angioplasty and Stenting
If blood thinners alone don’t relieve symptoms, doctors can thread a catheter into the blocked vein and inflate a small balloon to reopen it, sometimes placing a stent to keep it open. This works best when the blockage is short or membrane-like.
TIPS Procedure
When angioplasty isn’t feasible or doesn’t work, the next option is a procedure called TIPS, which creates an artificial channel inside the liver connecting a branch of the incoming blood supply directly to a draining vein. This bypasses the obstruction and lowers pressure throughout the liver. Results are encouraging: one large study of 35 patients reported 1-year and 5-year transplant-free survival rates of 93% and 74%. A European multicenter study of 157 patients found a 5-year transplant-free survival rate of 72%.
Liver Transplantation
For the 10% to 20% of patients who don’t respond to any of the above, or who present with fulminant liver failure or advanced cirrhosis, liver transplantation becomes necessary. One- and 5-year survival rates after transplant generally range from 76% to 95% and 65% to 95%, depending on the center and patient population. In Japan, where living-donor transplants are more common for this condition, 5- and 10-year survival rates after living-donor transplant have reached 81%.
Long-Term Risks
Even after successful treatment, Budd-Chiari syndrome carries a notable risk of liver cancer. The pooled prevalence of hepatocellular carcinoma among these patients is about 15.4%, which is considerably higher than in the general population. This risk exists because chronic congestion and scarring create an environment that promotes abnormal cell growth. Long-term imaging surveillance is a standard part of follow-up care.
Portal hypertension, the persistent elevation of pressure in the liver’s blood supply, is the main driver of ongoing complications in chronic cases. It can lead to enlarged veins in the esophagus or stomach that carry a risk of bleeding, as well as recurring fluid buildup in the abdomen.
Who Is Most Affected
Globally, the pooled annual incidence is about 1 per million people, with prevalence around 11 per million. The condition is roughly four times more commonly diagnosed in Europe (2 per million per year) than in Asia (0.47 per million per year), though differences in screening and reporting likely play a role. It tends to affect younger adults, particularly women of childbearing age, partly because pregnancy and hormonal contraceptives increase clotting risk in people who already carry genetic predispositions like Factor V Leiden.